Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial. REFLECT real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results